Bio-Techne (TECH) FY Conference Transcript

Summary of Biotechnology Management Presentation Company Overview - Company Name: Bio Techne - Headquarters: Minneapolis - Employees: Approximately 3,100 across 34 global locations - Industry: Biotechnology, focusing on protein-based reagents and products Core Business Segments - Segments: - Protein Sciences - Diagnostics and Spatial Biology - Revenue Breakdown (2024): - Total Revenue: $1.2 billion - 80% from consumables - 9% from instrumentation - 9% from services related to instrumentation - 2% from royalties - Revenue Composition: - 72% from Protein Sciences - 28% from Diagnostics and Spatial Biology, which has grown from 26% the previous year [8][9][10] Growth Factors and Market Trends - Key Growth Areas: - Discovery of novel biological insights - Development and manufacturing of advanced therapeutics - Enablement of precision diagnostics - Market Trends: - Multiomic insight generation - AI-enabled innovation - Novel therapeutic approaches like cell therapy - Precision medicine and healthy aging [16][18][19] Financial Performance - Recent Growth: - 1% growth during a challenging period, with a return to 6% organic growth year-to-date for fiscal year 2025 [34] - Operating Margins: - Targeting 35-40% EBITDA range, with a historical CAGR of 40% [34][45] - Market Position: - Positioned to outgrow the overall market by 500 to 1,000 basis points [44] Innovations and Product Development - Recent Launches: - LEO instrument for high-throughput western blotting - Multi-omic solutions for RNA and protein visualization - ESR1 kit for breast cancer management [26][29][31] - Acquisitions: - Focus on M&A to enhance product offerings and market position, particularly in high-margin or high-growth companies [36] Sustainability and Corporate Governance - Sustainability Initiatives: - Published fourth corporate sustainability report, focusing on reducing waste and improving environmental footprint [42] - Diversity and Inclusion: - Commitment to a diverse and inclusive workplace [43] Conclusion - Strategic Position: - Bio Techne has built a differentiated proteomic core portfolio over 48 years, addressing a $28 billion market opportunity with a strong innovation pipeline [44] - Future Aspirations: - Aim for sustainable financial performance while unlocking scientific possibilities [45]